News

The funding will be used for commercial readiness and the potential US launch of the company’s lead product candidate, AD109, pending approval by the US Food and Drug

The transaction will expand Neurocrine’s portfolio in endocrinology and rare diseases via the addition of Soleno’s lead product, Vykat XR (diazoxide choline), for Prader-Willi syndrome (PWS). Vykat XR

The project will enhance Aspect Biosystems’ clinical development capabilities and bolster its integrated platform for developing and manufacturing advanced cellular medicines. The investment is in addition to the

The approval in the European Union (EU) is for adults with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal carcinoma whose tumours are PD-L1 positive, with a combined

This follows the company’s signing of a definitive agreement in October 2025 to acquire the business. The deal adds advanced Protein A chromatography capabilities and Amsphere Protein A

Under the agreement, Biocytogen’s fully human antibody discovery platform will be combined with Sihuan Pharmaceutical’s capabilities in drug development, manufacturing, and commercialisation. The collaboration will focus on advanced

The IND includes results from completed toxicology, pharmacology, and manufacturing studies necessary for regulatory assessment. Pending IND clearance, Telomir Pharmaceuticals aims to start a Phase I/II clinical trial

The partnership aims to explore a new class of small molecules, called molecular glues, which enable or stabilise interactions between proteins. Molecular glues are an emerging therapeutic modality

The FDA approval of Ponlimsi is based on a comprehensive evidence package, including analytical and clinical data showing immunogenicity, safety, and similar efficacy to Prolia. Ponlimsi is approved